Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Viking Therapeutics (VKTX) to $99 from $102 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- These Are the Stocks Reporting Earnings Today – February 12, 2026
- Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c)
- Viking Therapeutics options imply 9.5% move in share price post-earnings
- VKTX Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, February 10 – February 13, 2026